

CURRENT LISTING OF CLAIMS

Claims 1-24 (cancelled).

25. **(Previously presented)** A conjugate comprising a Substance P analog and a polypeptide that inhibits protein synthesis, wherein the analog is selected from CYGGGGGGGRPKPQQFF SarLMet(O₂)-amide (SEQ ID NO:1) and CYGGGGGGGRPKPQQFFGLM-amide (SEQ ID NO:2).
26. **(Previously presented)** The conjugate of claim 25, wherein said analog of Substance P is CYGGGGGGGRPKPQQFF SarLMet(O₂)-amide (SEQ ID NO:1).
27. **(Previously presented)** The conjugate of claim 25, wherein said analog of Substance P is CYGGGGGGGRPKPQQFFGLM-amide (SEQ ID NO:2).
28. **(Previously presented)** The conjugate of claim 25, wherein said polypeptide that inhibits protein synthesis is attached to said Substance P analog through a disulfide linkage.
29. **(Previously presented)** The conjugate of claim 25, wherein said polypeptide that inhibits protein synthesis is saporin.
30. **(Previously presented)** The conjugate of claim 25, wherein said polypeptide that inhibits protein synthesis is a ribosome-inactivating protein.
31. **(Previously presented)** The conjugate of claim 30, wherein said ribosome-inactivating protein is selected from ricin A chain, gelonin and pokeweed antiviral protein.
32. **(Previously presented)** The conjugate of claim 25, wherein said polypeptide that inhibits protein synthesis is a toxin.
33. **(Previously presented)** The conjugate of claim 32, wherein said toxin is diphtheria toxin A fragment or an analog thereof that inhibits protein synthesis.
34. **(Previously presented)** The conjugate of claim 32, wherein said toxin is pseudomonas aeruginosa exotoxin A fragment or an analog thereof that inhibits protein synthesis.

35. **(Previously presented)** A pharmaceutical composition comprising a therapeutically effective amount of the conjugate of claim 25, and a pharmaceutically acceptable carrier.

36. **(Previously presented)** A pharmaceutical composition comprising a therapeutically effective amount of the conjugate of claim 29, and a pharmaceutically acceptable carrier.

37. **(Previously presented)** The conjugate of claim 31, wherein said ribosome-inactivation protein is ricin A chain.

38. **(Previously presented)** The conjugate of claim 31, wherein said ribosome-inactivation protein is gelonin.

39. **(Previously presented)** The conjugate of claim 31, wherein said ribosome-inactivation protein is pokeweed antiviral protein.

40. **(Previously presented)** The conjugate of claim 25, wherein said polypeptide that inhibits protein synthesis is attached to said Substance P analog through a chemical bond.

41-56. **(Cancelled)**